News

Life Sciences

Agenus Closes Immuno-Oncology Deal with Gilead

Edward Kim | Equities.com |

$150 million up front + up to $1.7 billion in milestone payments.


TG Therapeutics Gets Breakthrough Therapy Designation for Lymphoma Treatment

Edward Kim | Equities.com |

Umbralisib is in Phase 3 trials in hematologic malignancies.


Avita Medical Begins Nationwide Launch of RECELL System for Severe Burns

Edward Kim | Equities.com |

Company also closes 2nd tranche of AUD 40 million equity offering.


Aerpio Completes Patient Dosing in Phase 2b Diabetic Retinopathy Study

Edward Kim | Equities.com |

Previous data has shown improvement in diabetic retinopathy and kidney function.


Alpine Immune Sciences Raises $25 Million in Private Placement of Stock + Warrants

Edward Kim | Equities.com |

Company recently showed positive data in cancer and graft versus host disease.


CEL-SCI Regains Full Compliance with NYSE American's Continued Listing Requirements

Edward Kim | Equities.com |

Company awaits final Phase 3 data in head and neck cancer (Image: CEL-SCI)


Amneal Gets Approval for Generic Version of Exelon Patch for Dementia

Edward Kim | Equities.com |

First transdermal product for this fast growing generic manufacturer (Image: Amneal Pharmaceuticals).


8 Biotech IPOs Delayed by the Government Shutdown

Edward Kim | Equities.com |

The delays could cause companies to seek alternative financing and put development pipelines on hold.


AgeX Therapeutics Reports Publication of Data Supporting Type II Diabetes and Obesity Therapy

Edward Kim | Equities.com |

Data in peer-reviewed journal support AgeX's stem cell therapeutic approach to metabolic diseases.


Dyadic International — Microcap Play in Multibillion-Dollar Biosimilars Market

Edward Kim | Equities.com |

Presenting at Biotech Showcase, Wednesday, Jan. 9, at 9am PT


Emerging Growth

Q BioMed Inc

Q BioMed Inc is a biomedical acceleration and development company. The company is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences…

Events

Truth on Trial: Implications for Communicators – Part III

Truth on Trial” is just one of a series of forums put on by the Schar School of Policy & Government, whose panelists are among the most influential legal, communications,…

Learn more